Idorsia Ltd (IDIA) - Total Liabilities

Latest as of March 2026: CHF1.66 Billion CHF ≈ $2.09 Billion USD

Based on the latest financial reports, Idorsia Ltd (IDIA) has total liabilities worth CHF1.66 Billion CHF (≈ $2.09 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Idorsia Ltd growing its equity to track the company's year-over-year net asset growth rate.

Idorsia Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how Idorsia Ltd's total liabilities have evolved over time, based on quarterly financial data. See IDIA FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Idorsia Ltd Competitors by Total Liabilities

The table below lists competitors of Idorsia Ltd ranked by their total liabilities.

Company Country Total Liabilities
Hubei Heyuan Gas Co Ltd
SHE:002971
China CN¥4.62 Billion
AcadeMedia AB (publ)
ST:ACAD
Sweden Skr16.12 Billion
Wangneng Environment Co Ltd
SHE:002034
China CN¥6.45 Billion
Rackspace Technology Inc
NASDAQ:RXT
USA $3.98 Billion
Jadard Technology Inc. A
SHG:688252
China CN¥454.01 Million
Lindab International AB
ST:LIAB
Sweden Skr7.31 Billion
Vertex
NASDAQ:VERX
USA $967.86 Million
Chengdu Information Technology of Chinese Academy of Sciences Co Ltd
SHE:300678
China CN¥381.12 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Idorsia Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Idorsia Ltd market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.60 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.41 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 3.45 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Idorsia Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Idorsia Ltd (2016–2025)

The table below shows the annual total liabilities of Idorsia Ltd from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 CHF1.60 Billion
≈ $2.03 Billion
-6.69%
2024-12-31 CHF1.72 Billion
≈ $2.17 Billion
+16.98%
2023-12-31 CHF1.47 Billion
≈ $1.86 Billion
-6.16%
2022-12-31 CHF1.57 Billion
≈ $1.98 Billion
+13.52%
2021-12-31 CHF1.38 Billion
≈ $1.74 Billion
+62.23%
2020-12-31 CHF849.88 Million
≈ $1.07 Billion
+1.19%
2019-12-31 CHF839.85 Million
≈ $1.06 Billion
+12.11%
2018-12-31 CHF749.14 Million
≈ $947.12 Million
+35.62%
2017-12-31 CHF552.37 Million
≈ $698.34 Million
+35.67%
2016-12-31 CHF407.15 Million
≈ $514.75 Million
--

About Idorsia Ltd

SW:IDIA Switzerland Biotechnology
Market Cap
$1.96 Billion
CHF1.55 Billion CHF
Market Cap Rank
#8642 Global
#119 in Switzerland
Share Price
CHF6.12
Change (1 day)
-1.45%
52-Week Range
CHF2.43 - CHF6.89
All Time High
CHF33.62
About

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more